



Pierre Kemula, B.Sc. is CureVac's Chief Financial Officer since 2016. Previously, he was the Chief Financial Officer of Pixium Vision, where he successfully contributed to the listing of the company on Euronext in Paris, and Vice President of Corporate Finance, Treasury and Financial Markets at Ipsen. Earlier in his career, Mr. Kemula worked with major strategy consulting firms (Roland Berger, Bossard Consultants and Gemini Consulting). He holds a Bachelor of Science in Management Sciences from the London School of Economics (LSE) in the United Kingdom.

Baron Jean Stéphane, MSc, MBA has served as a member of CureVac's supervisory board since 2016. Since 2018 Mr. Stéphane serves as the Chairman of the board at Bone Therapeutics. Mr. Stéphane was the CEO of GSK Biologicals from 1989 until 2012 and the President of GSK Biologicals from 2002 until 2012 where he was instrumental in building one of the world's leading vaccine companies. In 1974 Mr. Stéphane joined SmithKline-Rit, as engineer in biology in research and development. He also served as the President of UWE (Union Wallonne des Entreprises) from 1997 until 2000. Mr. Stéphane was the chairman of BESIX Group S.A./N.V. and TiGenix N.V., IBA Wallonia Foreign Trade and Investment Agency, Henogen S.A., Aseptic Technologies. He was also a director of Fortis bank and GBL.